Pharmalittle: Sanofi reduces cost of well-known insulin by 78%; Califf condemns insurers for inadequate investment in drug research.

As another work week comes to an end, it's time to start thinking about weekend plans. Our plans are simple: taking a leisurely walk with our beloved mascot, catching up on some much-needed sleep, and having a listening party with Mrs. Pharmalot. We've already got a few things on our schedule, but what about you? With spring just around the corner, it might be a good time to start cleaning up your home. Alternatively, you could book a vacation or stay at home and binge-watch your favorite TV shows. Whatever you decide to do, make sure to stay safe and have a great time. We'll see you soon.

Like its competitors, Sanofi will reduce the cost of its widely-prescribed insulin in the U.S. by 78%. Additionally, for commercially insured patients who take Lantus, the company will limit out-of-pocket costs to $35. STAT reports that Eli Lilly and Novo Nordisk also decided to lower the list prices of some insulin products earlier in the month. The three companies manufacture most of the insulin products and account for 80% of the market share. Over time, they have been heavily criticized for consistently increasing prices in unison.

Gain access to this content by signing up for STAT+ and receive your initial month at no charge.

Republishing works from the Author

The author of the Pharmalot column, who is also a senior writer, wrote an article in a different language and needs it to be rewritten in free English. So, I am rewriting this particular blog section using different words.

Ed Silverman reports on the pharmaceutical sector.

How to Make a Display Name for Commenting

Your comment will be accompanied by this name.